BOTHELL, Wash.--(BUSINESS WIRE)--May. 31, 2012--
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management
will present at the following upcoming investor conferences. The
presentations will be webcast live and available for replay from Seattle
Genetics’ website at www.seattlegenetics.com
in the Investors
and News section.
|
Jefferies 2012 Global Healthcare Conference
|
|
Wednesday, June 6 at 11:30 a.m. Eastern time in New York, NY
|
|
|
|
Bank of America Merrill Lynch 2012 Smid Cap Conference
|
|
Thursday, June 7 at 3:05 p.m. Eastern time in Boston, MA
|
|
|
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of monoclonal antibody-based therapies for the
treatment of cancer. The U.S. Food and Drug Administration granted
accelerated approval of ADCETRIS® (brentuximab vedotin) in
August 2011 for two indications. ADCETRIS is being developed in
collaboration with Millennium: The Takeda Oncology Company. In addition,
Seattle Genetics has three other clinical-stage antibody-drug conjugate
(ADC) programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has
collaborations for its ADC technology with a number of leading
biotechnology and pharmaceutical companies, including Abbott, Bayer,
Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline,
Millennium, Pfizer and Progenics, as well as ADC co-development
agreements with Agensys, an affiliate of Astellas, and Genmab. More
information can be found at www.seattlegenetics.com.
Source: Seattle Genetics, Inc.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
